;
Written by, Keith Javery, D.O.
Dr. Javery and Dr. Suderman were invited to present to the inaugural meeting of the Midwest Society of Interventional Pain Physicians in Chicago, Illinois the weekend of June 8 – 10, 2018. This was a meeting of the top experts of interventional pain specialists from the entire Midwest and upper Midwest involving the best specialists from Michigan, Ohio, Indiana, Illinois, Wisconsin, Kentucky, and Iowa
Dr. Javery was asked to lecture on the current state of the medical insurance industry as it relates to the treatment of the suffering chronic pain patient. He gave a well-received and detailed lecture about the indications as well as the procedural and physician requirements to perform certain types of advanced interventional pain procedures that are very common and very beneficial for millions of chronic pain patients, and he also compared and lectured on the fact that there are other insurance third party vendors (eviCore Healthcare LLC) that among others have placed significant restrictions to receive these helpful, pain-reducing, and life-enhancing interventions. Dr. Javery’s lecture was well received and most in attendance stated they found the information very helpful and hopefully all of the physicians were in attendance will work with their patients to try to advocate changes in how some of these insurance guideline authorization entities such as eviCore, Noridian, and others have placed severe barriers for many types of interventional treatments that have been documented in solid peer-reviewed literature to be of great value in improving the daily life of those who unfortunately suffer from chronic daily pain.
Dr. Suderman as well as Dr. Javery also lectured on the Javery Pain institute’s proprietary “accelerated intravenous Buprenorphine induction.” The use of Buprenorphine, which is a synthetic partial agonist narcotic, has been proven to be very beneficial for a large percentage of patients who suffer from chronic pain that still require narcotic therapy but this particular medicine for many patients seems to provide excellent pain relief with a lower incidence of significant and potentially even fatal side effects. This was very well received by the various experts throughout the Midwest and upper Midwest who specialize in pain medicine, and hopefully the introduction of this proprietary and novel induction technique will spur more investigation at Javery Pain Institute as well as promote insurance carriers and even governmental insurance carriers to cover the cost of this medicine since it seems to be useful for many patients that don’t have either the option or have not responded to traditional narcotic therapy.
